BECLOMETHASONE 50 PRESSURISED 50MCG INHALER

Indications

• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Allergic rhinitis
• Nasal polyps

Dosage

Children: For children aged 5 to 12 years with asthma, the usual inhaled dose is 50 to 200 micrograms twice daily. For allergic rhinitis, refer to the BNF for Children

Adults: For asthma, the usual dose of inhaled beclomethasone is 100 to 400 micrograms twice daily, adjusted based on clinical response. For allergic rhinitis, 200 to 400 micrograms as a nasal spray may be administered once daily.

Mechanism of action

Beclomethasone acts by binding to glucocorticoid receptors in the cytoplasm of target cells. This complex translocates to the nucleus, where it influences gene transcription, leading to the downregulation of pro-inflammatory cytokines and the upregulation of anti-inflammatory proteins. This mechanism results in decreased inflammation, mucus production, and airway hyper-responsiveness.

Pharmacodynamics

The anti-inflammatory effects of beclomethasone are attributed to its ability to inhibit the release of inflammatory mediators, including leukotrienes and prostaglandins. It also reduces the recruitment of inflammatory cells to the site of inflammation. The onset of action for inhaled beclomethasone may take several hours to days, with maximum benefits typically observed after continuous use.

Pharmacokinetics

Beclomethasone is well-absorbed following inhalation, with a significant portion undergoing first-pass metabolism in the liver, thereby reducing systemic exposure. Its half-life is approximately 2.5 hours, but the duration of action may extend due to the drug's accumulation in lung tissue. The elimination of beclomethasone is primarily hepatic, with metabolites excreted in urine and feces.

Contra-indications

• Hypersensitivity to beclomethasone or any of its components
• Untreated systemic fungal infections

Adverse effects

• Cushing's syndrome
• Adrenal suppression
• Osteoporosis
• Growth retardation in children
• Skin thinning
• Increased risk of infections
• Oral candidiasis

Interactions

• CYP3A4 inhibitors may increase systemic exposure to beclomethasone
• Vaccines (live) may have reduced efficacy

Precautions

• Use with caution in patients with active or quiescent tuberculosis
• Monitor for signs of adrenal insufficiency
• Consider risks in patients with diabetes mellitus
• Use with caution in patients with hypertension

Pregnancy

Beclomethasone is classified as category C. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Beclomethasone is excreted in breast milk, caution should be exercised when administering to nursing women.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Inhalation aerosol
• Nasal spray
• Topical cream
• Topical lotion

Indications

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Allergic Rhinitis
• Cystic Fibrosis
• Pulmonary Hypertension

Dosage

Children: Refer to specific inhaled medication guidelines for paediatric dosing.

Adults: Refer to specific inhaled medication guidelines for adult dosing.

Mechanism of action

Inhaled medications can have various mechanisms of action depending on the specific drug. For example, beta-2 adrenergic agonists stimulate beta-2 receptors on bronchial smooth muscle, leading to bronchodilation. Corticosteroids inhibit the expression of inflammatory mediators and reduce airway inflammation, while anticholinergics block acetylcholine from binding to its receptors, resulting in decreased bronchoconstriction.

Pharmacodynamics

The pharmacodynamics of inhaled medications involve their interaction with specific receptors or pathways in the lungs. Bronchodilators cause relaxation of the bronchial smooth muscle, leading to increased airflow. Corticosteroids effectively reduce inflammation and mucus production in the airways, thereby improving respiratory function and reducing exacerbations of asthma and COPD. The rapid delivery of these drugs to the site of action enhances their efficacy.

Pharmacokinetics

Inhaled medications have distinct pharmacokinetic properties. The onset of action can be very rapid, often within minutes, due to direct delivery to the lungs. The bioavailability depends on factors such as particle size, inhalation technique, and the type of inhaler used. Systemic absorption is generally lower than with oral medications, which minimizes systemic side effects. The duration of action varies based on the specific drug class; for example, short-acting beta agonists provide quick relief, while long-acting agents offer prolonged effects.

Pregnancy

Consult healthcare provider for risk assessment and guidance, as safety data may vary depending on the specific inhalation formulation.

Breast-feeding

Consult healthcare provider, as some inhalation medications may be excreted in breast milk and could affect the infant.

Storage

Store in a cool, dry place away from direct sunlight. Check specific product guidelines for temperature and humidity requirements.

Indications

• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Exercise-induced bronchoconstriction
• Allergic rhinitis (in some cases)

Dosage

Children: Refer to specific product guidelines for dosage, as it varies by formulation and active ingredient.

Adults: Refer to specific product guidelines for dosage, as it varies by formulation and active ingredient.

Mechanism of action

The mechanism of action varies depending on the active ingredient in the pressurized formulation. For example, beta-2 adrenergic agonists, such as albuterol, work by stimulating beta-2 adrenergic receptors in bronchial smooth muscle, leading to relaxation and bronchodilation. Corticosteroids, like fluticasone, exert their effects by binding to glucocorticoid receptors, inhibiting the inflammatory response, and reducing airway hyperreactivity.

Pharmacodynamics

The pharmacodynamics of pressurized medications involve their ability to produce a therapeutic effect through local action in the lungs. The onset of action can be rapid, particularly for bronchodilators, which may relieve symptoms of bronchospasm within minutes. The efficacy of corticosteroids develops over time, reducing inflammation and improving lung function. The therapeutic effect is often measured by improvements in airflow, reduced symptoms, and decreased need for rescue medication.

Pharmacokinetics

Pharmacokinetics of pressurized medications can vary widely based on the specific drug. Generally, these agents have a rapid absorption and onset of action due to their delivery route. Systemic absorption may occur, especially with corticosteroids, leading to potential systemic effects. The distribution of the drug can be localized primarily in the lungs, with varying degrees of systemic bioavailability. Metabolism and excretion also depend on the specific active ingredients, with many being metabolized in the liver and excreted via the kidneys.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when using during breastfeeding. It is not known whether the drug is excreted in human milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.